The biotechnology revolution is underway. In the last fifteen years, the emergence of new technologies and new socioeconomic paradigms has radically changed the way we innovate and invest in the future of our health.
As a result, biotechnology has become one of the largest and most profitable investment sectors in the world. A quarter of the world's venture capital investment goes to this sector, with returns that have been exceeding 20% per year for many years.
Capital Cell opens up an access route for private investors to an asset that, until now, was reserved for a few specialists or people with large fortunes.
This platform was created to make the work of a highly specialized team of professional investors, lawyers, financiers, scientists and health experts from around the world available to everyone.
It has never been so easy to invest in the most profitable sector with the greatest social impact.
Licence/regulation: CAPITAL CELL licensed under European Crowdfunding Service Providers (ECSP) regulation
Capital Cell operates as an Equity crowdfunding platform offering investors to invest in startups and early-stage companies through acquiring company shares. On the other hand offering companies am alternative fundraising tool to raise funds from a large pool of investors.
On Capital Cell you can invest in European startups from healthcare and biotech industries
When investing on Capital Cell you invest in early-stage companies which makes it a high-risk investment since statistically 9 of 10 early-stage companies fail. You as an investor have to carefully evaluate such investments including product, product-market fit, company team and their ability to successfully develop a company, total addressable and reachable market and company growth potential, and other risks depending on business specifics.
This platform have no rating yet. Be the first to rate!